Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced the launch of its SignalStar Multiplex IHC technology, a revolutionary new tool for spatial biology research using mid-plex, high-throughput immunohistochemistry (IHC) assays. The SignalStar technology labels up to eight targets in formalin-fixed, paraffin-embedded (FFPE) tissues simultaneously with flexible, highly validated antibody panels ready to interrogate cellular presence, location, function, and biomarker coexpression patterns. The SignalStar Multiplex IHC assay uses a proprietary technology to amplify the antibody signals, allowing for the detection of targets with low expression levels for up to eight proteins in a single tissue.
